http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 23 Sep 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Graycliff+Drilling+and+Corporate+Update/27093352.html <p>Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - <b>Graycliff Exploration Limited</b> <b>(CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0)</b> ("Graycliff" or the "Company") is pleased to provide an operational update on its 2026 exploration drilling campaign at its 100-per-cent-owned Shakespeare gold project located near Sudbury, Ontario. The Company has now successfully completed an additional five core holes since the last update on August 26, 2026.</p><p>"We are making good progress with our 2026 drilling campaign at Shakespeare," stated James Macintosh, Chairman. "We continue to see strong alteration zones and dark sulfide-bearing fractured quartz vein material where anticipated, which leads us to http://www.streetinsider.com/Press+Releases/Graycliff+Drilling+and+Corporate+Update/27093352.html Wed, 23 Sep 2026 07:30:00 -0400 GRAY GRYCF http://www.streetinsider.com/Press+Releases/Graycliff+Drilling+and+Corporate+Update/27093352.html <p>Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - <b>Graycliff Exploration Limited</b> <b>(CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0)</b> ("Graycliff" or the "Company") is pleased to provide an operational update on its 2026 exploration drilling campaign at its 100-per-cent-owned Shakespeare gold project located near Sudbury, Ontario. The Company has now successfully completed an additional five core holes since the last update on August 26, 2026.</p><p>"We are making good progress with our 2026 drilling campaign at Shakespeare," stated James Macintosh, Chairman. "We continue to see strong alteration zones and dark sulfide-bearing fractured quartz vein material where anticipated, which leads us to http://www.streetinsider.com/Press+Releases/Graycliff+Drilling+and+Corporate+Update/27093352.html Wed, 23 Sep 2026 07:30:00 -0400 GRAY GRYCF http://www.streetinsider.com/Newsfile/Graycliff+Drilling+and+Corporate+Update/27093352.html <p>Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - <b>Graycliff Exploration Limited</b> <b>(CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0)</b> ("Graycliff" or the "Company") is pleased to provide an operational update on its 2026 exploration drilling campaign at its 100-per-cent-owned Shakespeare gold project located near Sudbury, Ontario. The Company has now successfully completed an additional five core holes since the last update on August 26, 2026.</p><p>"We are making good progress with our 2026 drilling campaign at Shakespeare," stated James Macintosh, Chairman. "We continue to see strong alteration zones and dark sulfide-bearing fractured quartz vein material where anticipated, which leads us to http://www.streetinsider.com/Newsfile/Graycliff+Drilling+and+Corporate+Update/27093352.html Wed, 23 Sep 2026 07:30:00 -0400 GRAY GRYCF http://www.streetinsider.com/Newsfile/Graycliff+Drilling+and+Corporate+Update/27093352.html <p>Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - <b>Graycliff Exploration Limited</b> <b>(CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0)</b> ("Graycliff" or the "Company") is pleased to provide an operational update on its 2026 exploration drilling campaign at its 100-per-cent-owned Shakespeare gold project located near Sudbury, Ontario. The Company has now successfully completed an additional five core holes since the last update on August 26, 2026.</p><p>"We are making good progress with our 2026 drilling campaign at Shakespeare," stated James Macintosh, Chairman. "We continue to see strong alteration zones and dark sulfide-bearing fractured quartz vein material where anticipated, which leads us to http://www.streetinsider.com/Newsfile/Graycliff+Drilling+and+Corporate+Update/27093352.html Wed, 23 Sep 2026 07:30:00 -0400 GRAY GRYCF http://www.streetinsider.com/IPOs/Grayscale+%28GRAY%29+files+for+proposed+NYSE+IPO/25603164.html (Updated - November 13, 2025 8:56 AM EST) <p>Grayscale (GRAY) files for proposed NYSE IPO.</p><p>The company describes itself as: "Grayscale is the largest digital asset-focused investment platform in the world, with approximately $35 billion in assets under management as of September 30, 2025. Our mission is to make digital asset investing simple and open to every investor. Founded in 2013, we have pioneered regulated access to the digital asset class. Our platform spans the full spectrum of institutional-grade solutions, providing investors with the broadest and most diverse suite of digital asset-focused investment products in the United States based on number of http://www.streetinsider.com/IPOs/Grayscale+%28GRAY%29+files+for+proposed+NYSE+IPO/25603164.html Thu, 13 Nov 2025 08:56:57 -0400 GRAY http://www.streetinsider.com/Trader+Talk/Grayscale+%28GRAY%29+files+for+proposed+NYSE+IPO/25603164.html (Updated - November 13, 2025 8:56 AM EST) <p>Grayscale (GRAY) files for proposed NYSE IPO.</p><p>The company describes itself as: "Grayscale is the largest digital asset-focused investment platform in the world, with approximately $35 billion in assets under management as of September 30, 2025. Our mission is to make digital asset investing simple and open to every investor. Founded in 2013, we have pioneered regulated access to the digital asset class. Our platform spans the full spectrum of institutional-grade solutions, providing investors with the broadest and most diverse suite of digital asset-focused investment products in the United States based on number of http://www.streetinsider.com/Trader+Talk/Grayscale+%28GRAY%29+files+for+proposed+NYSE+IPO/25603164.html Thu, 13 Nov 2025 08:56:57 -0400 GRAY http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684